Globe News Wire
15 Sept 2026, 06:30 UTC · 1d ago
Verdict
Headline takes no side. Three claims average +0.30 — moderately bullish.
+0.30moderately bullish
More positive than 65% of claims this week
Scored by the NIS engine · methodology.
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
eleva GmbH is separating its operations into two standalone companies: Eleva Biologics (platform partnerships) and One04 Therapeutics (CPV-104 clinical development).
Newannounced today, September 15, 2026
More positive than 77% of claims this week
One04 Therapeutics will advance CPV-104, a first-in-class recombinant human Factor H therapy, into late-stage clinical development.
Continue reading
5 related stories
Top 3 movers · tap to explore
So whatHaving successfully passed Phase 1, the asset now enters the higher-risk, higher-cost Phase 2/3 window where clinical efficacy is proven.
More positive than 65% of claims this week
Eleva Biologics will utilize its moss-based Bryotechnology platform to pursue a partnership-led business model for complex biologics.
Newannounced today, September 15, 2026
More positive than 55% of claims this week
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
6h ago
